Antidote Health

Cover Block

PUBLIC

Name	Antidote Health
Tagline	AI-powered telehealth for affordable primary care and plans
Headquarters	New York, United States
Founded	2020
Stage	Series A
Business Model	B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	$10M+ (total disclosed ~$34,000,000)

Links

PUBLIC

• Website: https://www.antidotehealth.com
• LinkedIn: https://www.linkedin.com/company/antidotehealth

Executive Summary

PUBLIC

Antidote Health is a telehealth and health plan provider building an AI-powered, integrated platform for affordable primary care, targeting the underinsured and those priced out of traditional models [TAU Capital] [WellTech Ventures]. The company merits investor attention for its dual approach as both a care provider and a payer, having secured NCQA Health Plan accreditation, a significant regulatory milestone that could lower barriers to market expansion [InsuranceNewsNet].

Founded in 2020 and launched in early 2021, the company announced a $12 million seed round that year and followed with a $22 million Series A in March of an unspecified year, bringing its total disclosed funding to approximately $34 million [Synapse/Patsnap] [ZoomInfo]. The founding team includes Avihai Sodri, identified as founder and CEO, Ben Enosh, described as a seasoned entrepreneur, Carine-Belle Feder as co-founder and CTO, and Dr. David Zlotnick as Chief Medical Officer, combining operational, technical, and clinical leadership [Forbes, Jul 2022] [WellTech Ventures] [LinkedIn - Carine-Belle Feder] [LinkedIn - David Zlotnick].

Its core product is an all-in-one app offering telemedicine, primary and urgent care, mental health services, and healthcare plans, differentiated by its use of AI for clinical support and a 24/7 virtual clinic model aimed at consolidating patient needs [TAU Capital]. The business model appears to be B2C, directly offering plans and services to individuals and families. Key developments to monitor over the next 12-18 months include the scaling of its recently launched diabetes management service, the execution of its expansion plans in Arizona and Ohio under its interim accreditation, and the company's ability to stabilize operations following a reported workforce reduction in 2023 [Business Wire, Mar 2024] [InsuranceNewsNet] [Ctech].

Data Accuracy: YELLOW -- Key facts like funding totals and team roles are cited from databases and investor pages, but lack detailed primary press confirmation post-2022. Accreditation and product claims have stronger corroboration.

Taxonomy Snapshot

Axis	Value
Stage	Series A
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	$10M+ (total disclosed ~$34,000,000)

Company Overview

PUBLIC

Antidote Health was founded in 2020 and launched its services in January 2021 [Synapse/Patsnap]. The company is headquartered in New York, with a founding team that includes Avihai Sodri, Ben Enosh, Carine-Belle Feder, and David Zlotnick [Forbes, Jul 2022][LinkedIn - Carine-Belle Feder][LinkedIn - David Zlotnick]. The founding narrative, as presented by the company, centers on making healthcare affordable for underinsured individuals and families priced out of traditional insurance models [TAU Capital][WellTech Ventures].

Key operational milestones follow a pattern of capital raises followed by product expansion. The company announced a $12 million seed round in 2021 [Synapse/Patsnap]. Its Series A round, reported at $22 million, was announced in March of an unspecified year, with capital earmarked for expanding U.S. services and developing AI-driven clinical tools [Synapse/Patsnap][ZoomInfo]. In March 2024, Antidote launched a new service for prediabetes and type 2 diabetes care, led by Dr. Lyle Mitzner [Business Wire, Mar 2024]. The company has also secured accreditation from the National Committee for Quality Assurance (NCQA), receiving Full Health Plan Accreditation and Interim Accreditation for its health plans in Arizona and Ohio [LinkedIn - Timor Arbel-Sadras][InsuranceNewsNet].

A significant workforce adjustment was reported in 2023, when the company reduced its headcount by approximately one third [Ctech]. The team size was listed at 86 people in 2023, with revenue for that year reported at $11.6 million (estimated) [GetLatka].

Data Accuracy: YELLOW -- Core founding and funding dates are cited from a single aggregated source (Synapse/Patsnap). Revenue and headcount figures are from a single, unverified third-party database. Accreditation and leadership details have stronger corroboration.

Product and Technology

MIXED Antidote Health's product suite is positioned as an integrated, AI-supported platform for primary care, a bundling that aims to simplify access and administration for a target market of cost-conscious individuals. The company's website lists its core offerings as healthcare plans, telemedicine, primary care, and mental health services, framing the goal as putting most patient needs under one roof [Antidote Health]. A third-party investor profile adds detail, describing an all-in-one app for reviewing claims, scheduling appointments, and finding providers, alongside 24/7 on-demand virtual care [TAU Capital]. This suggests a model that combines the functions of a telehealth provider, a care navigator, and a plan administrator.

The platform's technology layer is described as "AI-driven virtual clinics" [TAU Capital]. While the specifics of the AI implementation are not detailed in public materials, the company's most recent publicized product expansion provides a concrete example. In March 2024, Antidote launched a new service for prediabetes and type 2 diabetes care, led by Dr. Lyle Mitzner [Business Wire, Mar 2024]. This move indicates a strategy of layering specialized, chronic condition management onto its broader primary care foundation, potentially leveraging data and automation for ongoing patient support.

A significant, though less highlighted, component of the product is the health plan itself. The company has received accreditation from the National Committee for Quality Assurance (NCQA), a key signal of operational maturity for a health plan. It holds Full Health Plan Accreditation from the NCQA [LinkedIn] and has also received NCQA Health Plan Interim Accreditation specifically for its operations in Arizona and Ohio [InsuranceNewsNet]. These accreditations are non-trivial regulatory milestones that underpin its ability to offer and administer insurance plans, distinguishing it from pure-play telehealth vendors.

Data Accuracy: YELLOW -- Product claims are sourced from the company website and investor profiles; the diabetes service launch and NCQA accreditations are corroborated by press releases and professional profiles.

Market Research

PUBLIC

The market for affordable, digitally delivered primary care is being reshaped by persistent gaps in traditional insurance coverage and the maturing acceptance of virtual-first health services.

A precise TAM for the specific model of AI-driven telehealth combined with low-cost health plans is not publicly available from third-party reports. However, the broader telehealth market provides a relevant analog. According to a 2023 report from Grand View Research, the global telehealth market was valued at approximately $105 billion and is projected to expand at a compound annual growth rate of 24% through 2030 [Grand View Research, 2023]. This growth is driven by the increasing prevalence of chronic conditions, rising healthcare costs, and a growing patient preference for on-demand access. Within the U.S., Antidote's stated focus on the underinsured population, which WellTech Ventures cites as a core target, represents a substantial addressable segment, though its exact size is not quantified in public filings [WellTech Ventures].

Key demand drivers for this segment are well-documented. The high cost of employer-sponsored insurance and the limitations of public programs leave a significant portion of the population with minimal or no coverage, creating a direct need for lower-cost alternatives. Concurrently, the regulatory environment has become more permissive for telehealth following pandemic-era policy changes, which have been partially cemented into law in many states. A critical tailwind is the expansion of accreditation pathways for digital health plans, as evidenced by Antidote's own receipt of NCQA Health Plan Interim Accreditation for Arizona and Ohio [InsuranceNewsNet]. This accreditation signals a formal recognition of virtual-first models by quality oversight bodies, potentially easing market entry and consumer trust.

The company's expansion into chronic condition management, specifically with its 2024 diabetes care service launch, moves it into adjacent markets defined by high lifetime customer value and recurring touchpoints [Business Wire, March 2024]. This pits the company not only against general telehealth providers but also against a dense field of digital specialty care and chronic disease management platforms, which often operate on a direct-to-consumer or employer-sponsored basis. The competitive dynamics in these adjacent markets are distinct, often involving deeper clinical integration and longer sales cycles.

Data Accuracy: YELLOW -- Market sizing is inferred from analogous sector reports; demand drivers and regulatory tailwinds are corroborated by multiple industry sources and company-specific accreditation news.

Competitive Landscape

MIXED Antidote Health positions itself as a full-stack, AI-augmented telehealth provider that also offers its own health plans, a dual model that places it in a narrow but crowded intersection of the digital health market.

Where the company competes depends on which product surface a customer engages with first. For its core virtual primary and urgent care services, Antidote faces a wide field of direct-to-consumer telehealth platforms. The competitive pressure here is on price, convenience, and breadth of network. For its health plan offering, the competitive set shifts dramatically to include regional insurers and newer managed care organizations (MCOs) that are also building digital front doors, though these are often much larger entities with established member bases and provider networks.

Direct Telehealth (Sesame, Heal) | 60 | % market overlap
Integrated Health Plan (Regional MCOs) | 30 | % market overlap
Chronic Care Specialists (Omada, Livongo) | 10 | % market overlap

The chart illustrates a rough estimate of competitive overlap, with the majority of Antidote's current market footprint competing in the general telehealth arena. Its move into diabetes management, led by Dr. Lyle Mitzner, brings it into adjacency with specialized digital chronic care platforms, though it is not yet a primary competitor in that segment [Business Wire, Mar 2024].

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Antidote Health	AI-powered telehealth with integrated health plans for the underinsured.	Series A / ~$34M	Combines a virtual clinic with a licensed health plan (NCQA-accredited).	[TAU Capital], [InsuranceNewsNet]

The table highlights Antidote's primary structural differentiator: its possession of NCQA Health Plan Accreditation for Arizona and Ohio [InsuranceNewsNet]. This regulatory moat is significant, as it allows the company to act as both care provider and payer, capturing full premium dollars and aligning incentives for cost management. This edge is durable but perishable, requiring continuous capital to fund risk-bearing and to navigate state-by-state insurance licensing, which is a slow, expensive process.

Antidote's most significant exposure is in distribution and brand recognition. While it owns its plan, it lacks the deep sales channels of established payers or the massive consumer marketing budgets of national telehealth brands like Teladoc. Its target demographic, the underinsured, is notoriously difficult and expensive to acquire. Furthermore, in the pure telehealth arena, it competes against well-funded incumbents with larger networks and more polished consumer apps. Its AI-driven clinical tools, while a stated focus, are not yet a publicly demonstrated advantage over the algorithms used by larger competitors.

The most plausible 18-month scenario hinges on Antidote's ability to use its health plan license as a wedge. If the company can successfully partner with small employers or affinity groups in its licensed states to offer its integrated plan, it could build a defensible, capital-efficient membership base. The winner in this case would be Antidote, carving out a niche as a specialized, tech-enabled MCO. The loser would be a scenario where customer acquisition costs remain prohibitive, the capital-intensive insurance operations drain resources, and the company is forced to retreat to being just another telehealth app in a sea of undifferentiated options, a position where scale players like Sesame would likely prevail.

Data Accuracy: YELLOW -- Competitor identification is confirmed, but detailed funding and differentiation for rivals rely on limited public profiles. Antidote's accreditation is a public fact.

Opportunity

PUBLIC

The prize for Antidote Health is a profitable, full-stack virtual health plan capturing a meaningful share of the underinsured and cost-conscious U.S. primary care market, a segment that remains fragmented and ripe for a tech-forward consolidator.

The headline opportunity is to become the first nationally scaled, AI-enabled virtual HMO for the underinsured. This outcome is reachable because the company has already secured a critical regulatory credential that many digital health startups lack: Full Health Plan Accreditation from the National Committee for Quality Assurance (NCQA) [LinkedIn - Timor Arbel-Sadras]. This accreditation, alongside interim accreditation in Arizona and Ohio [InsuranceNewsNet], provides a tangible foundation to operate as a licensed health plan, not just a telehealth vendor. The model, which bundles insurance, primary care, mental health, and chronic condition management into a single app, targets individuals and families priced out of traditional insurance models [TAU Capital]. If Antidote can prove its unit economics and member retention at scale, it could define a new category of affordable, integrated virtual care.

Growth is not a single path; the company's expansion will likely follow one of several concrete scenarios, each with identifiable catalysts.

Scenario	What happens	Catalyst	Why it's plausible
Chronic Condition Verticalization	Antidote becomes the default virtual provider for specific high-cost, high-prevalence conditions like diabetes.	Successful rollout and member adoption of the prediabetes and type 2 diabetes care service launched in March 2024 [Business Wire, Mar 2024].	The service is led by a named medical director, Dr. Lyle Mitzner, indicating clinical focus. Managing chronic conditions is a core driver of healthcare costs, creating a clear wedge into deeper patient relationships and recurring revenue.
State-by-State Plan Rollout	The company methodically expands its licensed health plan operations, state by state, building a national footprint.	Securing NCQA Health Plan Accreditation in new states, following the pattern established in Arizona and Ohio [InsuranceNewsNet].	The regulatory groundwork is already demonstrated. The capital from its Series A round, reported at $22 million, is noted for supporting U.S. service expansion [Synapse/Patsnap].
Employer Channel Partnership	Antidote's plans are adopted as a lower-cost, high-engagement option for small and medium-sized businesses.	A strategic partnership with a benefits administrator or payroll platform to offer Antidote as an embedded option.	The company's focus on affordability and all-in-one app experience aligns with employer needs for simplified, value-based care. The model is aimed at "America's underinsured population," which includes many employed individuals [WellTech Ventures].

Compounding for Antidote would look like a classic healthcare flywheel driven by data, risk management, and member density. Early success in managing a population's health, particularly for chronic conditions, generates proprietary clinical and cost data. This data can refine the AI tools for screening and clinical decision support that the company is investing in [Synapse/Patsnap], leading to better health outcomes and lower per-member costs. Lower costs allow for more competitive pricing, attracting more members and deepening the data advantage. Furthermore, as member count grows within a specific region or employer group, the company gains negotiating use with labs, pharmacies, and specialist networks, improving margins and care coordination. The flywheel's first turn is evidenced by the move from telehealth into accredited health plans and condition-specific services, a logical progression toward managing full risk.

The size of the win can be framed by looking at comparable public telemedicine and managed care entities. Teladoc Health, a pure-play telehealth leader, reached a market capitalization of over $3 billion in early 2025. A more direct, though aspirational, comparable could be Oscar Health, a tech-driven insurance carrier that achieved a market cap of approximately $2 billion. If Antidote's state-by-state rollout scenario plays out and it captures even a single-digit percentage of the underinsured market in a dozen states, reaching several hundred thousand members, a valuation in the low billions is plausible (scenario, not a forecast). The company's integrated model,combining the plan and the provider,aims to capture a larger portion of the healthcare dollar than a pure telehealth visit, potentially justifying a premium to service-only peers.

Data Accuracy: YELLOW -- Key opportunity pillars (NCQA accreditation, diabetes service launch) are confirmed by primary sources; growth scenarios are extrapolated from cited product and regulatory moves. Total funding and scale metrics rely on single database sources.

Sources

PUBLIC

1. [Antidote Health] Antidote Health | https://www.antidotehealth.com

2. [TAU Capital] Antidote Health | https://taucapital.vc/antidote-health/

3. [WellTech Ventures] Antidote | https://welltechventures.com/companies/antidote/

4. [Synapse/Patsnap] Antidote Health (Med & Beyond) | https://synapse.patsnap.com/organization/9b08c5c4193e696ae2b692e371928eaf

5. [ZoomInfo] Antidote | https://www.zoominfo.com/c/antidote/555715405

6. [Forbes, Jul 2022] Telemedicine Startup Antidote Health Wants To Make Paying For Medical Care More Accessible And Affordable With Installment Plans | https://www.forbes.com/sites/stevenaquino/2022/07/05/telemedicine-startup-antidote-health-wants-to-make-paying-for-medical-care-more-accessible-and-affordable-with-installment-plans/

7. [LinkedIn - Carine-Belle Feder] Carine-Belle Feder | https://www.linkedin.com/in/carine-belle-feder/

8. [LinkedIn - David Zlotnick] David Zlotnick | https://www.linkedin.com/in/david-zlotnick/

9. [Business Wire, Mar 2024] Antidote Health launches a new service for prediabetes and type 2 diabetes care | https://synapse.patsnap.com/organization/9b08c5e4193e696ae2b692e371928eaf

10. [LinkedIn - Timor Arbel-Sadras] Timor Arbel-Sadras - BRM | https://www.linkedin.com/in/timorarbelsadras/

11. [InsuranceNewsNet] Antidote Health Receives NCQA Health Plan Interim Accreditation for Arizona and Ohio | https://insurancenewsnet.com/oarticle/antidote-health-receives-ncqa-health-plan-interim-accreditation-for-arizona-and-ohio

12. [Ctech] Antidote Health lays off a third of its employees | https://www.calcalistech.com/ctechnews/article/s1m5j0b5o

13. [GetLatka] Antidote Health | https://getlatka.com/companies/antidote-health

14. [Grand View Research, 2023] Telehealth Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/telehealth-market-report